Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Itraconazole interaction study with AZD9291 in EGFR-mutant NSCLC after prior EGFR TKI
NL-OMON45155Phase 1Recruiting
- Sponsor
- AstraZeneca
- Start
- Jan 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of osimertinib and itraconazole in non-small cell lung cancer (NSCLC) (2 arms), sponsored by AstraZeneca. Primary endpoint: Effect of itraconazole on AZD9291 exposure. Started Jan 2015; status: recruiting.
02
Drugs
osimertinibitraconazole
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON45155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45155.